Does AXSM pay dividends?

Axsome Therapeutics Inc (AXSM) does not currently pay a regular dividend.

What is AXSM's market cap?

Axsome Therapeutics Inc (AXSM) has a market capitalization of $10.42B with a current stock price of $198.52.

Axsome Therapeutics Inc (AXSM)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$198.52

-0.50 (-0.25%)

Market Cap: $10.42B

Last updated: Sep 01, 2026 at 5:00 PM ET

Earnings

Performance (10Y)

Beat Rate

45%(18/40)

Avg Surprise

-7.73%

Streak

1 Q

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.41

Range$-0.73 - $-0.03

8 analysts

EPS Revisions

30d

EPS Estimate Drift

90d ago$-0.34+19.3%

60d ago$-0.33+19.4%

30d ago$-0.32+24.0%

7d ago$-0.31+26.1%

Current$-0.41

Revenue Consensus

$261M

Range$251M - $282M

14 analysts

Period ending Dec 31, 2026

EPS Consensus$-0.58

Range$-1.73 - $0.46

11 analysts

Revenue Consensus

$293M

Range$201M - $356M

20 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.58	$-1.73 - $0.46	-	-	11	-	-
Sep 30, 2026Sep 26EST	-	$-0.41	$-0.73 - $-0.03	-	-	8	1 0 30d	-
Jun 30, 2026Jun 26 Reported Aug 10, 2026Reported Aug 10	$-0.99	$-0.99	$-1.25 - $-0.05	+0.00%	Beat	11	1 0 30d	-2.1%
Mar 31, 2026Mar 26 Reported May 4, 2026Reported May 4	$-1.26	$-0.86	$-1.05 - $-0.21	-46.51%	Miss	6	1 2 30d	-3.3%
Dec 31, 2025Dec 25 Reported Feb 23, 2026Reported Feb 23	$-0.56	$-0.73	$-1.16 - $-0.28	+22.82%	Beat	15	4 1 30d	+63.6%
Sep 30, 2025Sep 25 Reported Nov 3, 2025Reported Nov 3	$-0.94	$-0.90	$-1.19 - $-0.57	-4.44%	Miss	14	1 3 30d	+30.0%
Jun 30, 2025Jun 25 Reported Aug 4, 2025Reported Aug 4	$-0.97	$-1.09	$-1.24 - $-0.75	+11.01%	Beat	13	0 6 30d	+41.9%
Mar 31, 2025Mar 25 Reported May 5, 2025Reported May 5	$-1.22	$-1.35	$-1.69 - $-0.81	+9.63%	Beat	10	1 3 30d	+15.3%
Dec 31, 2024Dec 24 Reported Feb 18, 2025Reported Feb 18	$-1.54	$-1.00	$-1.32 - $-0.55	-53.60%	Miss	11	6 2 30d	+26.0%
Sep 30, 2024Sep 24 Reported Nov 12, 2024Reported Nov 12	$-1.34	$-1.41	$-1.70 - $-0.78	+4.83%	Beat	16	3 0 30d	-1.7%
Jun 30, 2024Jun 24 Reported Aug 5, 2024Reported Aug 5	$-1.67	$-1.33	$-1.67 - $-0.97	-25.56%	Miss	16	2 0 30d	-8.4%
Mar 31, 2024Mar 24 Reported May 6, 2024Reported May 6	$-1.44	$-1.22	$-1.45 - $-0.98	-18.03%	Miss	15	2 1 30d	-453.8%
Dec 31, 2023Dec 23 Reported Feb 20, 2024Reported Feb 20	$-2.08	$-1.17	$-1.36 - $-1.07	-77.78%	Miss	14	2 1 30d	-47.5%
Sep 30, 2023Sep 23 Reported Nov 6, 2023Reported Nov 6	$-1.32	$-1.19	$-1.33 - $-0.93	-10.92%	Miss	11	2 0 30d	-23.4%
Jun 30, 2023Jun 23 Reported Aug 7, 2023Reported Aug 7	$-1.54	$-1.20	$-1.48 - $-0.97	-28.33%	Miss	11	6 0 30d	-45.3%
Mar 31, 2023Mar 23 Reported May 8, 2023Reported May 8	$-0.26	N/A	-	+75.00%	Beat	12	2 0 30d	+74.8%
Dec 31, 2022Dec 22 Reported Feb 27, 2023Reported Feb 27	$-1.41	$-1.14	$-1.59 - $-0.72	-23.68%	Miss	15	1 0 30d	-56.7%
Sep 30, 2022Sep 22 Reported Nov 7, 2022Reported Nov 7	$-1.07	$-1.10	$-1.63 - $-0.84	+2.73%	Beat	14	2 0 30d	-15.1%
Jun 30, 2022Jun 22 Reported Aug 9, 2022Reported Aug 9	$-1.06	$-1.12	$-2.28 - $-0.84	+5.36%	Beat	12	2 0 30d	-23.3%
Mar 31, 2022Mar 22 Reported May 2, 2022Reported May 2	$-1.03	$-1.01	$-1.35 - $-0.83	-1.98%	Miss	11	1 1 30d	-32.1%
Dec 31, 2021Dec 21 Reported Mar 1, 2022Reported Mar 1	$-0.90	$-1.02	$-1.46 - $-0.91	+11.76%	Beat	12	No revisions (30d)	-15.4%
Sep 30, 2021Sep 21 Reported Nov 8, 2021Reported Nov 8	$-0.93	$-0.93	$-1.22 - $-0.83	+0.00%	Beat	13	No revisions (30d)	-60.3%
Jun 30, 2021Jun 21 Reported Aug 9, 2021Reported Aug 9	$-0.86	$-0.88	$-1.56 - $-0.76	+2.27%	Beat	14	1 0 30d	-75.5%
Mar 31, 2021Mar 21 Reported May 10, 2021Reported May 10	$-0.78	$-0.81	$-1.49 - $-0.63	+3.70%	Beat	14	No revisions (30d)	+11.4%
Dec 31, 2020Dec 20 Reported Mar 1, 2021Reported Mar 1	$-0.78	$-0.76	$-1.52 - $-0.57	-2.63%	Miss	14	No revisions (30d)	-9.9%
Sep 30, 2020Sep 20 Reported Nov 5, 2020Reported Nov 5	$-0.58	$-0.55	$-0.76 - $-0.45	-5.45%	Miss	11	No revisions (30d)	-3.6%
Jun 30, 2020Jun 20 Reported Aug 10, 2020Reported Aug 10	$-0.49	$-0.61	$-0.87 - $-0.48	+19.67%	Beat	9	No revisions (30d)	-19.5%
Mar 31, 2020Mar 20 Reported May 8, 2020Reported May 8	$-0.88	$-0.62	$-0.69 - $-0.51	-41.94%	Miss	9	No revisions (30d)	-175.0%
Dec 31, 2019Dec 19 Reported Mar 12, 2020Reported Mar 12	$-0.71	$-0.46	$-0.63 - $-0.35	-54.35%	Miss	8	No revisions (30d)	-121.9%
Sep 30, 2019Sep 19 Reported Nov 7, 2019Reported Nov 7	$-0.56	$-0.39	$-0.46 - $-0.35	-43.59%	Miss	8	No revisions (30d)	-80.6%
Jun 30, 2019Jun 19 Reported Aug 8, 2019Reported Aug 8	$-0.41	$-0.31	$-0.33 - $-0.28	-32.26%	Miss	6	No revisions (30d)	-28.1%
Mar 31, 2019Mar 19 Reported May 9, 2019Reported May 9	$-0.32	$-0.30	$-0.35 - $-0.27	-6.67%	Miss	5	No revisions (30d)	-10.3%
Dec 31, 2018Dec 18 Reported Mar 14, 2019Reported Mar 14	$-0.32	$-0.30	$-0.33 - $-0.26	-6.67%	Miss	4	No revisions (30d)	-3.2%
Sep 30, 2018Sep 18 Reported Nov 9, 2018Reported Nov 9	$-0.31	$-0.28	$-0.28 - $-0.28	-10.71%	Miss	0	No revisions (30d)	-14.8%
Jun 30, 2018Jun 18 Reported Aug 8, 2018Reported Aug 8	$-0.32	$-0.27	$-0.32 - $-0.27	-18.52%	Miss	2	No revisions (30d)	-6.7%
Mar 31, 2018Mar 18 Reported May 8, 2018Reported May 8	$-0.29	$-0.28	$-0.28 - $-0.28	-3.57%	Miss	2	No revisions (30d)	+29.3%
Dec 31, 2017Dec 17 Reported Mar 7, 2018Reported Mar 7	$-0.31	$-0.31	$-0.31 - $-0.31	+0.00%	Beat	1	No revisions (30d)	+18.4%
Sep 30, 2017Sep 17 Reported Nov 8, 2017Reported Nov 8	$-0.27	$-0.34	-	+20.59%	Beat	-	-	+28.9%
Jun 30, 2017Jun 17 Reported Aug 9, 2017Reported Aug 9	$-0.30	$-0.34	-	+11.76%	Beat	-	-	-
Mar 31, 2017Mar 17 Reported May 9, 2017Reported May 9	$-0.41	$-0.39	-	-5.13%	Miss	-	-	-
Dec 31, 2016Dec 16 Reported Mar 7, 2017Reported Mar 7	$-0.38	$-0.42	-	+9.52%	Beat	-	-	-
Sep 30, 2016Sep 16 Reported Nov 14, 2016Reported Nov 14	$-0.38	$-0.39	-	+2.56%	Beat	-	-	-

Key Metrics

Valuation
P/E Ratio	-52.94	EV/EBITDA	-14.81x
Price/FCF	-142.90x	FCF Yield	-0.70%
Profitability
Profit Margin	-24.70%	Operating Margin	-23.40%
ROE	-245.10%	ROIC	-65.87%
Financial Health
Debt/Equity	2.39x	Interest Coverage	N/A
Current Ratio	1.43x	Quick Ratio	1.34x
Trading Statistics
Beta	0.73	Avg Volume	669.51K
52-Week High	$260.19	52-Week Low	$112.90

Technical Indicators Dashboard

Moving Averages

SMA 10$207.15

SMA 20$210.72

SMA 50$226.50

SMA 200$193.41

EMA 10$206.01

EMA 20$211.38

EMA 50$219.27

EMA 200$195.89

MACD

Line: -6.86Signal: -6.17Hist: -0.69

ADX

ADX: 23.0+DI: 12.7-DI: 28.7

Aroon & PSAR

Aroon UpN/A

Aroon Down100.0

PSAR$211.21

Bollinger Bands

Upper Band$222.63

Lower Band$198.80

%B Position1131%(Upper)

Band Width-0.01

RSI (14-Day)

Neutral

31.3

Momentum Oscillators

Stoch %K10.7

Stoch %D18.6

Williams %R-94.2

ROC (10d)-8.2%

Momentum-17.75

CCI (20d)-179.5

MFI (14d)32.9

Volatility Measures

ATR (14d)$7.39(3.7%)

StdDev (20d)5.96

Hist Vol28.6%(Moderate)

Volume Flow

VWAP$198.77

OBV14.8M

AD Line1.9M

CMF (20d)-0.190

Volume Metrics

Avg Vol (20d)654.8K

Vol Ratio0.8x

VWMA (20d)$211.93

Pivot Points

R3$210.18

R2$207.94

R1$203.48

Pivot Point$201.24

S1$196.78

S2$194.54

S3$190.08

Advanced Oscillators

TSI-26.39

Ultimate Osc36.3

KST-95.04

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$218.38M	$191.20M	$196.00M	$170.99M	$150.04M	$121.46M	$118.77M	$104.76M	$87.17M	$75.00M	$71.53M	$57.79M
Cost of Revenue	$13.56M	$14.72M	$12.33M	$11.91M	$13.45M	$9.79M	$10.51M	$8.44M	$8.05M	$6.30M	$7.38M	$6.53M
Gross Profit	$204.81M	$176.48M	$183.67M	$159.08M	$136.59M	$111.67M	$108.25M	$96.33M	$79.11M	$68.70M	$64.15M	$51.26M

Operating Expenses	$254.46M	$239.84M	$210.63M	$205.19M	$173.31M	$168.66M	$180.87M	$158.95M	$157.16M	$135.98M	$162.43M	$113.38M
R&D	$46.23M	$52.68M	$48.79M	$40.16M	$49.54M	$44.78M	$55.01M	$45.39M	$49.85M	$36.83M	$30.80M	$28.77M
SG&A	$208.14M	$185.00M	$169.30M	$150.24M	$130.28M	$120.79M	$113.27M	$95.56M	$103.55M	$98.97M	$86.81M	$83.19M
Operating Income	$-49,646,000	$-63,357,000	$-26,957,000	$-46,109,000	$-36,714,000	$-56,982,000	$-72,617,000	$-62,624,000	$-78,046,000	$-67,275,000	$-98,274,000	$-62,120,000

Interest Income	$-1,540,000	$-1,185,000	$-1,172,000	$-1,120,000	$-1,834,000	$-2,431,000	$-2,210,000	$-1,978,000	$-1,299,000	$-1,082,000	$-702,000	$-757,000
Interest Expense	$0	$1.19M	$1.17M	$0	$10.38M	$2.43M	$2.21M	$0	$0	$1.08M	$702,000	$757,000
Income Before Tax	$-51,186,000	$-64,542,000	$-28,129,000	$-47,229,000	$-48,933,000	$-59,413,000	$-74,827,000	$-64,602,000	$-79,345,000	$-68,357,000	$-98,976,000	$-62,877,000
Income Tax Expense	$128,000	$0	$430,000	$0	$-960,000	$0	$85,000	$0	$0	$0	$-325,000	$-678,000

Net Income	$-51,314,000	$-64,542,000	$-28,559,000	$-47,229,000	$-47,973,000	$-59,413,000	$-74,912,000	$-64,602,000	$-79,345,000	$-68,357,000	$-98,651,000	$-62,199,000

EBITDA	$-46,595,000	$-60,831,000	$-24,522,000	$-43,540,000	$-34,151,000	$-54,182,000	$-69,836,000	$-59,891,000	$-75,412,000	$-64,825,000	$-96,080,000	$-59,750,000
EBIT	$-49,646,000	$-63,357,000	$-26,957,000	$-46,109,000	$-36,714,000	$-56,982,000	$-72,617,000	$-62,624,000	$-78,046,000	$-67,275,000	$-98,274,000	$-62,120,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about AXSM

News

Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation

Axsome Therapeutics has initiated the SUMMIT Phase 3 trial for AXS-05, an investigational treatment for smoking cessation. The randomized, double-blind study will evaluate the efficacy and safety of AXS-05 against bupropion and placebo in adult smokers over a 12-week period. Smoking cessation addresses a significant public health need, with millions of U.S. adults smoking and a low success rate for unassisted quitting.

The Manila Times•Aug 31, 2026 5:01 PM8/31/26•

Bullish

Axsome Therapeutics Starts Phase 3 Trial of AXS-05 for Smoking Cessation

Axsome Therapeutics has initiated the SUMMIT Phase 3 trial for its investigational drug AXS-05, targeting smoking cessation. AXS-05 is also being developed for Alzheimer's disease agitation. The company is a biopharmaceutical firm focused on central nervous system conditions, with commercial products including AUVELITY, SUNOSI, and SYMBRAVO.

marketscreener.com•Aug 31, 2026 7:36 AM8/31/26•

Bullish

Jefferies Financial Group Inc. Invests $6.27 Million in Axsome Therapeutics, Inc. $AXSM

Jefferies Financial Group Inc. has acquired a new stake of 25,628 shares, valued at $6.27 million, in Axsome Therapeutics, Inc. (NASDAQ:AXSM) during the second quarter. Despite institutional investors owning 81.49% of the company, Axsome reported a quarterly loss and revenue that missed analyst estimates, with analysts forecasting a full-year loss of $2.80 per share. However, the stock maintains a "Moderate Buy" consensus rating with an average price target of $267.60, even as insiders have sold approximately $45.3 million in stock over the past three months.

MarketBeat•Aug 29, 2026 5:01 PM8/29/26•

Neutral

Hsbc Holdings PLC Invests $13.67 Million in Axsome Therapeutics, Inc. $AXSM

Hsbc Holdings PLC recently acquired 55,800 shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) valued at approximately $13.67 million, representing 0.11% of the company. Institutional investors collectively own 81.49% of AXSM, while analysts maintain a "Moderate Buy" rating with an average price target of $267.60. Despite this, insiders have been selling shares, totaling about $45.3 million in the past 90 days, including CEO Herriot Tabuteau's sale of nearly $12 million worth of stock.

MarketBeat•Aug 28, 2026 5:01 PM8/28/26•

Neutral

Canada Pension Plan Investment Board Invests $55.17 Million in Axsome Therapeutics, Inc. $AXSM

The Canada Pension Plan Investment Board has acquired a new stake of 225,400 shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) worth approximately $55.17 million. This investment comes despite Axsome Therapeutics missing its latest quarterly earnings and revenue estimates. Analysts maintain a "Moderate Buy" rating for AXSM with an average price target of $267.60.

MarketBeat•Aug 28, 2026 5:01 PM8/28/26•

Somewhat-Bullish

Frequently Asked Questions About AXSM

Does AXSM pay dividends?: Axsome Therapeutics Inc (AXSM) does not currently pay a regular dividend.
What is AXSM's market cap?: Axsome Therapeutics Inc (AXSM) has a market capitalization of $10.42B with a current stock price of $198.52.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In